The medicinal chemistry of theragnostics, multimodality imaging and applications of nanotechnology in cancer

Current Topics in Medicinal Chemistry

Volumn 10, Issue 12, 2010, Pages 1211-1226

  Majumdar, Debatosh ^a   Peng, Xiang Hong ^a   Shin, Dong M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Cancer; Imaging; Nanotechnology; Pharmacokinetics; Receptor; Theragnostics; Therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR; GADOLINIUM; GLUCOSE TRANSPORTER; INTEGRIN; METAL ORGANIC FRAMEWORK; SOMATOSTATIN RECEPTOR; STEROID RECEPTOR; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANGIOGENESIS; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FLUORESCENCE IMAGING; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CHEMISTRY, PHARMACEUTICAL; DIAGNOSTIC IMAGING; HUMANS; MOLECULAR PROBES; NANOMEDICINE; NEOPLASMS;

EID: 77955267200     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791384171     Document Type: Article

References (44)

1. http://www.who.int/cancer/en/; http://uicc.org/; http://www.iarc.fr/ [Accessed August 2009].
2. Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev., 1999, 99, 2293-2352.
3. Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer, 2002, 2, 683-693.
4. Willmann, J. K.; van Bruggen, N.; Dinkelborg, L. M.; Gambhir, S. S. Molecular imaging in drug development. Nat. Rev. Drug Discov., 2008, 7, 591-607.
5. Weissleder, R.; Mahmood, U. Molecular imaging. Radiology, 2001, 219, 316-333.
6. Massoud, T. F.; Gambhir, S. S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev., 2003, 17, 545-580.
7. Hoffman, J. M.; Gambhir, S. S. Molecular imaging: the vision and opportunity for radiology in the future. Radiology, 2007, 244, 39-47.
8. Peng, X. H.; Qian, X.; Mao, H.; Wang, A. Y.; Chen, Z. G.; Nie, S.; Shin, D. M. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int. J. Nanomed., 2008, 3, 311-321.
9. Devaraj, N. K.; Keliher, E. J.; Thurber, G. M.; Nahrendorf, M.; Weissleder, R. 18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjug. Chem., 2009, 20, 397-401.
10. Yang, L.; Mao, H.; Wang, Y. A.; Cao, Z.; Peng, X.; Wang, X.; Duan, H.; Ni, C.; Yuan, Q.; Adams, G.; Smith, M. Q.; Wood, W. C.; Gao, X.; Nie, S. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small, 2009, 5, 235-243.
11. Xu, H.; Baidoo, K.; Gunn, A. J.; Boswell, C. A.; Milenic, D. E.; Choyke, P. L.; Brechbiel, M. W. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumortargeted imaging. J. Med. Chem., 2007, 50, 4759-4765.
12. Xu, H.; Eck, P. K.; Baidoo, K. E.; Choyke, P. L.; Brechbiel, M. W. Toward preparation of antibody-based imaging probe libraries for dual-modality positron emission tomography and fluorescence imaging. Bioorg. Med. Chem., 2009, 17, 5176-5181.
13. Montet, X.; Weissleder, R.; Josephson, L. Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjug. Chem., 2006, 17, 905-911.
14. Pene, F.; Courtine, E.; Cariou, A.; Mira, J. P. Toward theragnostics. Crit. Care Med., 2009, 37, S50-S58.
15. Ozdemir, V.; Williams-Jones, B.; Glatt, S. J.; Tsuang, M. T.; Lohr, J. B.; Reist, C. Shifting emphasis from pharmacogenomics to theragnostics. Nat. Biotechnol., 2006, 24, 942-947.
16. Shubayev, V. I.; Pisanic, T. R.; Jin, S. H. Magnetic nanoparticles for theragnostics. Adv. Drug Deliv. Rev., 2009, 61, 467-477.
17. Del Vecchio, S.; Zannetti, A.; Fonti, R.; Pace, L.; Salvatore, M. Nuclear imaging in cancer theranostics. Q. J. Nucl. Med. Mol. Imaging, 2007, 51, 152-163.
18. Lucignani, G. Nanoparticles for concurrent multimodality imaging and therapy: the dawn of new theragnostic synergies. Eur. J. Nucl. Med. Mol. Imaging,2009, 36, 869-874.
19. Santra, S.; Kaittanis, C.; Grimm, J.; Perez, J. M. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small, 2009, 5, 1862-1868.
20. Pan, D.; Caruthers, S. D.; Hu, G.; Senpan, A.; Scott, M. J.; Gaffney, P. J.; Wickline, S. A.; Lanza, G. M. Ligand-directed nanobialys as theranostic agent for drug delivery and manganesebased magnetic resonance imaging of vascular targets. J. Am. Chem. Soc., 2008, 130, 9186-9187.
21. Rowe, M. D.; Thamm, D. H.; Kraft, S. L.; Boyes, S. G. Polymermodified gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer. Biomacromolecules, 2009, 10, 983-993.
22. Schmieder, A. H.; Caruthers, S. D.; Zhang, H.; Williams, T. A.; Robertson, J. D.; Wickline, S. A.; Lanza, G. M. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J., 2008, 22, 4179-4189.
23. Chong, H. S.; Song, H. A.; Ma, X.; Milenic, D. E.; Brady, E. D.; Lim, S.; Lee, H.; Baidoo, K.; Cheng, D.; Brechbiel, M. W. Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI. Bioconjug. Chem., 2008, 19, 1439-1447.
24. Chong, H. S.; Garmestani, K.; Bryant, L. H., Jr.; Milenic, D. E.; Overstreet, T.; Birch, N.; Le, T.; Brady, E. D.; Brechbiel, M. W. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging. J. Med. Chem., 2006, 49, 2055-2062.
25. Chong, H. S.; Ma, X.; Le, T.; Kwamena, B.; Milenic, D. E.; Brady, E. D.; Song, H. A.; Brechbiel, M. W. Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy. J. Med. Chem., 2008, 51, 118-125.
26. Milenic, D. E.; Brady, E. D.; Brechbiel, M. W. Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discov., 2004, 3, 488-499.
27. Dolmans, D. E.; Fukumura, D.; Jain, R. K. Photodynamic therapy for cancer. Nat. Rev. Cancer, 2003, 3, 380-387.
28. Zhang, M.; Zhang, Z.; Blessington, D.; Li, H.; Busch, T. M.; Madrak, V.; Miles, J.; Chance, B.; Glickson, J. D.; Zheng, G. Pyropheophorbide 2-deoxyglucosamide: a new photosensitizer targeting glucose transporters. Bioconjug. Chem., 2003, 14, 709-714.
29. Chen, Y.; Gryshuk, A.; Achilefu, S.; Ohulchansky, T.; Potter, W.; Zhong, T.; Morgan, J.; Chance, B.; Prasad, P. N.; Henderson, B. W.; Oseroff, A.; Pandey, R. K. A novel approach to a bifunctional photosensitizer for tumor imaging and phototherapy. Bioconjug. Chem., 2005, 16, 1264-1274.
30. Pandey, S. K.; Sajjad, M.; Chen, Y.; Zheng, X.; Yao, R.; Missert, J. R.; Batt, C.; Nabi, H. A.; Oseroff, A. R.; Pandey, R. K. Comparative positron-emission tomography (PET) imaging and phototherapeutic potential of 124I- labeled methyl- 3-(1'- iodobenzyloxyethyl)pyropheophorbide-a vs the corresponding glucose and galactose conjugates. J. Med. Chem., 2009, 52, 445-455.
31. Medina, R. A.; Owen, G. I. Glucose transporters: expression, regulation and cancer. Biol. Res. 2002, 35, 9-26.
32. Nicholson, R. I.; McClelland, R. A.; Gee, J. M. Steroid hormone receptors and their clinical significance in cancer. J. Clin. Pathol., 1995, 48, 890-895.
33. Kochanny, M. J.; VanBrocklin, H. F.; Kym, P. R.; Carlson, K. E.; O'Neil, J. P.; Bonasera, T. A.; Welch, M. J.; Katzenellenbogen, J. A. Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors. J. Med. Chem., 1993, 36, 1120-1127.
34. Zhou, D.; Carlson, K. E.; Katzenellenbogen, J. A.; Welch, M. J. Bromine- and iodine-substituted 16alpha,17alpha-dioxolane progestins for breast tumor imaging and radiotherapy: synthesis and receptor binding affinity. J. Med. Chem., 2006, 49, 4737-4744.
35. Froidevaux, S.; Heppeler, A.; Eberle, A. N.; Meier, A. M.; Hausler, M.; Beglinger, C.; Behe, M.; Powell, P.; Macke, H. R. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acidsomatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology, 2000, 141, 3304-3312.
36. Reubi, J. C.; Maurer, R.; von Werder, K.; Torhorst, J.; Klijn, J. G.; Lamberts, S. W. Somatostatin receptors in human endocrine tumors. Cancer Res., 1987, 47, 551-558.
37. Clifford, T.; Boswell, C. A.; Biddlecombe, G. B.; Lewis, J. S.; Brechbiel, M. W. Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide. J. Med. Chem., 2006, 49, 4297-4304.
38. Cai, W.; Chen, X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med., 2008, 49 (Suppl. 2), 113S-128S.
39. Philip, R.; Murthy, S.; Krakover, J.; Sinnathamby, G.; Zerfass, J.; Keller, L.; Philip, M. Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J. Proteome Res., 2007, 6, 2509-2517.
40. McCarthy, J. R.; Jaffer, F. A.; Weissleder, R. A macrophagetargeted theranostic nanoparticle for biomedical applications. Small, 2006, 2, 983-987.
41. Tassinari, O. W.; Caiazzo, R. J., Jr.; Ehrlich, J. R.; Liu, B. C. Identifying autoantigens as theranostic targets: antigen arrays and immunoproteomics approaches. Curr. Opin. Mol. Ther., 2008, 10, 107-115.
42. Warenius, H. M.; Seabra, L.; Kyritsi, L.; White, R.; Dormer, R.; Anandappa, S.; Thomas, C.; Howarth, A. Theranostic proteomic profiling of cyclins, cyclin dependent kinases and Ras in human cancer cell lines is dependent on p53 mutational status. Int. J. Oncol., 2008, 32, 895-907.
43. Gorelik, B.; Ziv, I.; Shohat, R.; Wick, M.; Hankins, W. D.; Sidransky, D.; Agur, Z. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res., 2008, 68, 9033-9040.
44. Kurihara, Y.; Watanabe, Y.; Onimatsu, H.; Kojima, T.; Shirota, T.; Hatori, M.; Liu, D.; Kyo, S.; Mizuguchi, H.; Urata, Y.; Shintani, S.; Fujiwara, T. Telomerase-specific virotheranostics for human head and neck cancer. Clin. Cancer Res., 2009, 15, 2335-2343.